# An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies

> **NCT07668453** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Biliary Tract Neoplasms

## Interventions

- **BIOLOGICAL:** Adebrelimab
- **DRUG:** gemcitabine
- **DRUG:** Albumin-Bound Paclitaxel /nab-Paclitaxel

## Key facts

- **NCT ID:** NCT07668453
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668453, "An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*